Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases

International Journal of Surgical Pathology

Volumn 22, Issue 2, 2014, Pages 136-148

  Pelosi, Giuseppe ^a,b   Haspinger, Eva Regina ^a   Bimbatti, Manuela ^a   Leone, Giorgia ^a   Paolini, Biagio ^a   Fabbri, Alessandra ^a   Tamborini, Elena ^a   Perrone, Federica ^a   Testi, Adele ^a   Garassino, Marina ^a   Maisonneuve, Patrick ^c   De Braud, Filippo ^a   Pilotti, Silvana ^a   Pastorino, Ugo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

chemotherapy; immunohistochemistry; lung cancer; p40; survival; TTF 1

Indexed keywords

AFATINIB; ANTINEOPLASTIC METAL COMPLEX; CRIZOTINIB; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; NIVOLUMAB; PACLITAXEL; PEMETREXED; THYROID TRANSCRIPTION FACTOR 1;

ADENOSQUAMOUS CARCINOMA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORPHOLOGY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HEALTH SURVEY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATION; NOMENCLATURE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

CHEMOTHERAPY; IMMUNOHISTOCHEMISTRY; LUNG CANCER; P40; SURVIVAL; TTF-1;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84898946210     PISSN: 10668969     EISSN: 19402465     Source Type: Journal    
DOI: 10.1177/1066896913511527     Document Type: Article

References (53)

1. Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med. 2008 ; 132: 384-396
2. Cagle PT, Allen TC, Dacic S, et al. Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med. 2011 ; 135: 110-116
3. Brown AF, Sirohi D, Fukuoka J, et al. Tissue-preserving antibody cocktails to differentiate primary squamous cell carcinoma, adenocarcinoma, and small cell carcinoma of lung. Arch Pathol Lab Med. 2013 ; 137: 1274-1281
4. Sterlacci W, Savic S, Schmid T, et al. Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact. Am J Clin Pathol. 2012 ; 137: 946-956
5. Kayser G, Csanadi A, Otto C, et al. Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples. PLoS One. 2013 ; 8: e56333
6. Rossi G, Pelosi G, Barbareschi M, et al. Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice. Int J Surg Pathol. 2013 ; 21: 326-336
7. Travis W, Brambilla E, Muller-Hermelink H, Harris C Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press ; 2004 :
8. Travis W, Colby T, Corrin B, Shimosato Y, Brambilla E Hystological Typing of Lung and Pleural Tumours. New York, NY: Springer Verlag ; 1999 :
9. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013 ; 31: 992-1001
10. Ellis PM, Blais N, Soulieres D, et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol. 2011 ; 6: 1379-1391
11. Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol. 2006 ; 59: 790-800
12. Rehm HL. Disease-targeted sequencing: a cornerstone in the clinic. Nat Rev Genet. 2013 ; 14: 295-300
13. Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol. 2010 ; 5: 411-414
14. Travis W, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 ; 6: 244-285
15. Pelosi G, Fabbri A, Bianchi F, et al. DeltaNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol. 2012 ; 7: 281-290
16. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. 2011 ; 6: 451-458
17. Sigel CS, Moreira AL, Travis WD, et al. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol. 2011 ; 6: 1849-1856
18. Sigel CS, Rudomina DE, Sima CS, et al. Predicting pulmonary adenocarcinoma outcome based on a cytology grading system. Cancer Cytopathol. 2012 ; 120: 35-43
19. Pelosi G. The new taxonomy of lung adenocarcinoma stemming from a multidisciplinary integrated approach: novel pathology concepts and perspectives. J Thorac Oncol. 2011 ; 6: 241-243
20. Bishop JA, Teruya-Feldstein J, Westra WH, et al. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012 ; 25: 405-415
21. Travis WD, Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med. 2011 ; 32: 22-31
22. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011 ; 12: 175-180
23. Pelosi G, Rossi G, Cavazza A, et al. DeltaNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. Int J Surg Pathol. 2013 ; 21: 229-239
24. Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med. 2013 ; 137: 668-684
25. Kadota K, Suzuki K, Kachala SS, et al. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol. 2012 ; 25: 1117-1127
26. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010 ; 34: 1155-1162
27. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011 ; 24: 653-664
28. Rekhtman N, Tafe LJ, Chaft JE, et al. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Mod Pathol. 2013 ; 26: 511-522
29. Hartel PH, Hartel JV, Fanburg-Smith JC, et al. Toward personalized medicine of lung cancer: response to nontargeted therapy in invasive pulmonary adenocarcinoma as a function of tumor cell differentiation. Int J Surg Pathol. 2013 ; 21: 224-228
30. Sobin L, Gospodarowicz M, Wittekind C TNM Classification of Malignant Tumours. New York, NY: Wiley-Blackwell ; 2010 :
31. Pelosi G, Rossi G, Bianchi F, et al. Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol. 2011 ; 6: 1039-1049
32. Pelosi G, Gasparini P, Cavazza A, et al. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. Lung Cancer. 2012 ; 77: 507-514
33. Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med. 2013 ; 137: 685-705
34. Rossi G, Papotti M, Barbareschi M, Graziano P, Pelosi G. Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer. J Clin Oncol. 2009 ; 27: e141 - e142
35. Warth A, Muley T, Herpel E, et al. Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology. 2012 ; 61: 1017-1025
36. Pelosi G, Sonzogni A, Viale G. The classification of lung carcinoma: time to change the morphology-based approach?. Int J Surg Pathol. 2010 ; 18: 161-172
37. Sun Z, Aubry MC, Deschamps C, et al. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovasc Surg. 2006 ; 131: 1014-1020
38. Barbareschi M, Cantaloni C, Del Vescovo V, et al. Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. Am J Clin Pathol. 2011 ; 136: 773-782
39. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer. 2011 ; 117: 3416-3423
40. Rossi G, Marchioni A, Milani M, et al. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol. 2004 ; 122: 884-893
41. Pardo J, Martinez-Penuela AM, Sola JJ, et al. Large cell carcinoma of the lung: an endangered species?. Appl Immunohistochem Mol Morphol. 2009 ; 17: 383-392
42. Bordoni A, Bongiovanni M, Mazzucchelli L, Spitale A. Impact of histopathological diagnosis with ancillary immunohistochemical studies on lung cancer subtypes incidence and survival: a population-based study. J Cancer Epidemiol. 2011 ; 2011: 275758
43. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 2012 ; 18: 1167-1176
44. HwangDHSzetoDPPerryASBruceJLShollLM. Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma [published online June5, 2013]. Arch Pathol Lab Med. doi:http://dx.doi.org/10.5858/arpa.2013-0179-OA
45. Thunnissen E, Boers E, Heideman DA, et al. Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma. Virchows Arch. 2012 ; 461: 629-638
46. Alsdorf WH, Clauditz TS, Hoenig T, et al. Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer. Exp Mol Pathol. 2013 ; 94: 155-159
47. Pelosi G, Fraggetta F, Pasini F, et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol. 2001 ; 25: 363-372
48. Holgersson G, Bergstrom S, Bergqvist M, et al. Swedish Lung Cancer Radiation Study group: predictive value of histology for radiotherapy response in patients with non-small cell lung cancer. Eur J Cancer. 2011 ; 47: 2415-2421
49. Guo S, Reddy CA, Chao ST, et al. Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases. Lung Cancer. 2012 ; 77: 389-393
50. Mujoomdar A, Austin JH, Malhotra R, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology. 2007 ; 242: 882-888
51. Cakir E, Demirag E, Aydin M, Unsal E. Clinicopathologic features and prognostic significance of lung tumours with mixed histologic patterns. Acta Chir Belg. 2009 ; 109: 489-493
52. Cooke DT, Nguyen DV, Yang Y, et al. Survival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomy. Ann Thorac Surg. 2010 ; 90: 943-948
53. Filosso PL, Ruffini E, Asioli S, et al. Adenosquamous lung carcinomas: a histologic subtype with poor prognosis. Lung Cancer. 2011 ; 74: 25-29